Most Read Articles
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 2 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
6 days ago

It appears that patients with rheumatoid arthritis (RA) are at an increased risk of obstructive sleep apnoea (OSA) secondary to both traditional and RA-related risk factors, a recent study has found.

Yesterday
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.

E-cigarettes may help smokers quit

03 Jan 2018
Vaping can help cut rates of smoking, says Reason Foundation think tank

Electronic nicotine delivery systems (ENDS) appear to aid in smoking cessation, a recent randomized naturalistic trial has shown.

The study included 68 adult smokers with minimal ENDS experience who were randomized to receive 16 mg of ENDS (n=25), 24 mg of ENDS (n=21), or no ENDS (n=22). Upon trial initiation, cigarettes per day (CPD) dropped, particularly for the 16-mg (mean 8.4 CPD) and 24-mg (mean 5.3 CPD) groups. In comparison, control participants averaged 11.2 CPD. The trial lasted for 3 weeks.

During the 21-day trial period, cigarette consumption of the participants who received the 16-mg and 24-mg ENDS decreased by 30.2 and 45.1 percent, respectively, while consumption of the control group increased by 0.7 percent.

By the end of the trial period, 35 and 30 percent of the 24-mg and 16-mg ENDS groups, respectively, reduced their smoking by at least half from baseline levels. Only 5 percent of the control group reached this level of smoking reduction (p=0.07 overall).

The motivation to quit was also significantly higher in ENDS participants, regardless of dose, than in controls (p=0.05 overall).

While none of the cessation-related behaviours were significantly more apparent in any particular group, the incidence rates of 24-hour quit attempts (odds ratio [OR], 3.1; 95 percent CI, 0.8–11.5) and floating abstinence (OR, 6.7; 0.7–61.9) showed positive trends in favour of ENDS participants.

The current study shows that in a real-world setting, there is a strong interest in ENDS among smokers, and that use of the technology may help in smoking cessation.

ENDS technology, which includes e-cigarettes and vaping devices, has attracted much attention because of its potential in helping with smoking cessation. However, there have been some inconsistencies in the literature, and the existing studies are limited either by self-selected samples or unrealistic e-cigarette prescriptions. [Addict Behav 2014;39:491-494; Am J Public Health 2017;105:1213-1219]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 2 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
6 days ago

It appears that patients with rheumatoid arthritis (RA) are at an increased risk of obstructive sleep apnoea (OSA) secondary to both traditional and RA-related risk factors, a recent study has found.

Yesterday
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.